A novel prognostic model for extranodal natural killer/T-cell lymphoma

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2183-2190

  Huang, Jia Jia ^a   Zhu, Ying Jie ^a   Xia, Yi ^a   Zhao, Wei ^a   Lin, Tong Yu ^a   Jiang, Wen Qi ^a   Huang, Hui Qiang ^a   Li, Zhi Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Extranodal natural killer T cell lymphoma; International Prognostic Index; Korean NK T cell lymphoma Prognostic Index; Overall survival; Prognostic model

Indexed keywords

ANTHRACYCLINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; NONBIOLOGICAL MODEL; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RISK FACTORS; YOUNG ADULT;

EID: 84872815509     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0030-x     Document Type: Article

References (25)

1. Lim MS, de Leval L, Quintanilla-Martinez L. Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms. J Hematop. 2009.
2. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931-7.
3. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009; 100(12):2242-8.
4. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin N Am. 1991;5(5):983-1001.
5. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16(2):206-14.
6. Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009;15(8):2905-12.
7. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216-21.
8. Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008;19(8):1477-84.
9. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106(12):3785-90.
10. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612-8.
11. Oshimi K, Kawa K, Nakamura S, Suzuki R, Suzumiya J, Yamaguchi M, et al. NK-cell neoplasms in Japan. Hematology. 2005;10(3):237-45.
12. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011;22(1):149-55.
13. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol. 2001;19(4):129-50.
14. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31(11):1860-1.
15. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med. 1993;329(14):987-94.
16. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
17. Grillo-Lopez AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann Oncol. 2000;11(4):399-408.
18. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(1):181-9.
19. You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15(4):618-25.
20. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000; 22(4):215-20.
21. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182-90.
22. Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007; 18(8):1382-7.
23. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186-94.
24. Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1093-101.
25. Liang X, Graham DK. Natural killer cell neoplasms. Cancer. 2008;112(7):1425-36.